5-methoxy-1'-(tetrahydro-2H-pyran-4-ylmethyl)spiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one | 1019767-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-methoxy-1'-(tetrahydro-2H-pyran-4-ylmethyl)spiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one
• 英文别名: 5-methoxy-1'-(oxan-4-ylmethyl)spiro[2H-furo[2,3-c]pyridine-3,3'-indole]-2'-one
• CAS: 1019767-60-2
• 化学式: C₂₁H₂₂N₂O₄
• 分子量: 366.417
• InChiKey: KZVVOAQYEOHGGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  60.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-溴甲基四氢吡喃 、 5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one 在 caesium carbonate 作用下， 以 丁酮 为溶剂， 反应 1.5h， 以89%的产率得到5-methoxy-1'-(tetrahydro-2H-pyran-4-ylmethyl)spiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one
  参考文献：
  名称：

  WO2008/46049

  摘要：

  公开号：

文献信息

• RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Buckmelter Alexandre J.

  公开号：US20100063066A1

  公开（公告）日：2010-03-11

  Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物(I)、(IIA)和(IIIA)的配方对抑制Raf激酶和治疗由此介导的疾病很有用。公开了使用化合物(I)、(IIA)和(IIIA)及其立体异构体和药用盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病或相关病理状况的方法。
• SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN
  申请人：Cadieux Jean-Jacques

  公开号：US20110294842A9

  公开（公告）日：2011-12-01

  This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R 1 , R 2a , R 2b , R 2c , R 2d and R 3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及使用式（I）的螺环氧吲哚化合物的方法：其中j、k、m、Q、X、R1、R2a、R2b、R2c、R2d和R3如此定义，作为立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、N-氧化物、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，如疼痛。
• SPIRO (FURO Ý3, 2-C¨PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN
  申请人：Xenon Pharmaceuticals Inc.

  公开号：EP2076514A1

  公开（公告）日：2009-07-08
• [EN] RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE LA KINASE RAF ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2008028141A2

  公开（公告）日：2008-03-06

  [EN] Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
  [FR] L'invention concerne des composés de formules (I), (IIA) et (IIIA) à utiliser pour inhiber la kinase Raf et pour traiter des états dont la médiation est assurée par ladite kinase. L'invention concerne également des procédés d'utilisation desdits composés de formules (I), (IIA) et (IIIA), de stéréoisomères et de sels acceptables sur le plan pharmaceutique de ceux-ci, pour le diagnostic, la prévention ou le traitement in vitro, in situ, et in vivo desdits états dans des cellules mammifère, ou d'états pathologique associés.
• [EN] SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN<br/>[FR] DÉRIVÉS DE SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE ET COMPOSÉS CONNEXES UTILISABLES POUR TRAITER DES MALADIES DONT LA MÉDIATION EST ASSURÉE PAR LES CANAUX SODIQUES, COMME LA DOULEUR
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2008046049A1

  公开（公告）日：2008-04-17

  [EN] This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X,, R¹, R^2a, R^2b, R^2c, R^2d and R³ are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
  [FR] La présente invention concerne des procédés d'utilisation de composés de spiro-oxindole de formule (I) : dans laquelle j, k, m, Q, X,, R¹, R^2a, R^2b, R^2c, R^2d et R³ sont tels que définis ici, en tant que stéréoisomère, énantiomère, tautomère de ceux-ci ou que mélanges de ceux-ci; ou un sel, un N-oxyde, un solvate ou un promédicament pharmaceutiquement acceptable de ceux-ci, pour le traitement et/ou la prévention de maladies ou d'affections induites par les canaux sodiques telles que la douleur.